FilingSEC EDGAR8-K
Filana Therapeutics Reports Q3 2026 Results and Simufilam Clinical Update
· SEC accepted
StagePhase 2a
Filing content
Filana reported Q3 2026 financial results and provided an update on the preparation for its Phase 2a clinical trial of simufilam following the lifting of the FDA clinical hold.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…